Further investigation of the potential benefit of HER2 targeted therapy in ILC, which predominately lacks HER2-amplified disease, is warranted to ensure optimal outcomes in this understudied tumor subtype currently treated similarly to the more common ductal cancers. Here, ERBB2 is linked to neoplasm.